HSBC Call 100 BAYN 16.12.2026/ DE000HG2TT92 /
15/11/2024 16:01:07 | Chg.+0.005 | Bid15/11/2024 | Ask15/11/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.006EUR | +500.00% | 0.006 Bid Size: 50,000 |
0.022 Ask Size: 50,000 |
BAYER AG NA O.N. | 100.00 - | 16/12/2026 | Call |
GlobeNewswire
02/08
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
11/07
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
30/05
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
30/05
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
28/05
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
02/05
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
18/04
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
16/04
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
11/04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
25/03
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
06/03
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
15/02
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust